Big pharma pushes Trump team to ease Medicare drug price negotiation rules
By Michael Erman, Patrick Wingrove and Maggie Fick NEW YORK (Reuters) – The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump is back in office, according to lobbyists, executives, analysts and healthcare policy experts. Seven lobbyists and executives who work with top pharmaceutical and biotech companies told Reuters they are pushing to delay the timeline under which medications … Read more…